FYI:
The table below lists the angiogenesis inhibitors now in clinical
trials, and whether they are in Phase I, II, or III. The NCI is
involved in the evaluation of thalidomide and Col-3 and is negotiating
with biotechnology companies to work on other compounds, some of which
are listed below:DRUG, PHASE OF TRIAL, SPONSOR
-TNP-470, Phase II, TAP Pharmaceuticals, Inc., Deerfield, Wis.
-Squalamine, Phase I, Magainin Pharmaceuticals, Inc., PlymouthMeeting, Pa.
-Vitaxin, Phase I, Ixsys, Inc. San Diego, Calif.
-Thalidomide, Phase II against Kaposi's sarcoma, breast, prostate and
primary brain cancers, EntreMed, Inc., Rockville, Md.
-RhuMab, VEGF, Phase II, Genentech, Inc., South San Francisco, Calif.
-SU5416, Phase I, Sugen, Inc., Redwood City, Calif.
-Marimastat, Phase III against pancreas, lung, gastric and breast
cancers and glioma, British Biotech, Inc., Annapolis, Md.
-Bay 12-9566, Phase III against lung and pancreas cancers Bayer
Corp., West Haven, Conn.
-AG3340, Phase III against lung and prostate cancers, Agouron
Pharmaceuticals, Inc., LaJolla, Calif.
-Col-3, Phase I, CollaGenex Pharmaceuticals, Inc., Newton, Pa.
-CM101, Phase I, Carbomed, Brentwood, Tenn. |
